Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.

@article{Bissler2016EverolimusFR,
  title={Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.},
  author={John J. Bissler and John Christopher Kingswood and Elżbieta Radzikowska and Bernard A Zonnenberg and Michael D. Frost and Elena D Belousova and Matthias A. Sauter and Norio Nonomura and Susanne Brakemeier and Petrus J de Vries and Noah C Berkowitz and Sara Miao and Scott Segal and S{\'e}verine Peyrard and Klemens Budde},
  journal={Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association},
  year={2016},
  volume={31 1},
  pages={111-9}
}
BACKGROUND Mammalian target of rapamycin (mTOR) inhibitors are recommended as first-line treatment of renal angiomyolipoma associated with tuberous sclerosis complex (TSC) or sporadic lymphangioleiomyomatosis (sporadic LAM), but follow-up is limited. Longer term efficacy and tolerability data from a Phase 3, double-blind, placebo-controlled trial are presented. METHODS Following favorable results from the primary analysis (data cutoff 30 June 2011) of the EXIST-2 trial, patients still… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 36 extracted citations

Similar Papers

Loading similar papers…